Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.35 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474457 | 0.83 | MCHR1 (0.37) | MCHR1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1473820 | 0.79 | TRPV1 (0.40) | MAPTMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL15797826 | 0.74 | HRH3 (0.52) | LTC4SMAPTHPGDSMN1; SMN2 | |
| SCHEMBL18828640 | 0.74 | HRH3 (0.52) | LTC4SMAPTHPGDSMN1; SMN2 | |
| SCHEMBL15797825 | 0.74 | HRH3 (0.52) | LTC4SMAPTHPGDSMN1; SMN2 | |
| SCHEMBL15805085 | 0.74 | HRH3 (0.52) | LTC4SMAPTHPGDSMN1; SMN2 | |
| SCHEMBL15805108 | 0.74 | HRH3 (0.52) | LTC4SMAPTHPGDSMN1; SMN2 | |
| SCHEMBL1474885 | 0.73 | KMT2A (0.37) | MAP3K5CXCR2CA12CA1CA2 | |
| SCHEMBL543490 | 0.70 | GAA (0.40) | MAP3K5CXCR2LTC4SCYP1A2TSHR | |
| SCHEMBL6082093 | 0.69 | KDM4E (0.47) | MAPTALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| CN-101160285-A | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists | PFIZER (US) | 2008-04-09 | — | — | CN | disclosed |
| EP-1861359-A1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097817-A9 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC (JP) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006097817-A1 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | MCHR1 180/4885MAP3K5 4019/4885TUBB4A 4731/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | MCHR1 180/4885MAP3K5 4041/4885TUBB4A 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.